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Abstract
S6 kinase, a member of AGC family of protein kinases and a downstream effector of 
mTORC1 pathway has over the years found much relevance in maintaining a normal cel-
lular state by virtue of its established role in regulation of cell growth and proliferation. 
S6 kinase activity has been linked to different cellular processes like glucose homeostasis, 
translational and transcriptional regulation. Hence any dysregulation in S6K1 leads to 
the emergence of various pathological conditions like diabetes, cancer and obesity. It is as 
such S6 kinase has emerged as a potential target for therapeutic interventions employed 
in curing such diseases. The Present Chapter reviews the regulation of S6K1, its struc-
tural organization and functions, besides highlighting its potential to act as an alternative 
therapeutic target for various cancerous situations exhibiting deranged mTOR signaling 
so as to overcome the possibility of relapses observed otherwise while using conven-
tional drugs
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1. Introduction
Cell signaling pathways function as cohorts to contribute in maintaining cellular homeosta-
sis-a phenomenon that remains pivotal in regulating cell growth and survival. The unique 
but immensely coordinated response of these diverse signals is primarily regulated by the 
availability of nutrients, growth factors and energy status of the cell. The signals destined 
to activate certain cellular functions may simultaneously be antagonistic for other func-
tions; to strike a much required balance for proper functioning of the cell. Relentless efforts 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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over the last several decades have led to recognize the ability of these signaling networks 
to promote cell growth and proliferation by way of their potential to phosphorylate one 
another to distinguish themselves as kinases. The kinases specifically transfer the phospho-
ryl group from ATP to their substrates such as to bring about a change in their function that 
helps transduce the upstream signals for the accomplishment of functions. Intrigued by the 
properties of these kinases, the scientific community over the years has shown great inter-
est in identifying more kinases that lead to the identification of a family of protein kinases 
known as ribosomal S6 kinases (RSKs) that respond to nutrients and growth factors. The 
RSKs came to fore after studying the inducible phosphorylations on ribosomal protein S6 
(rps6) and accordingly p90 ribosomal S6 kinase was identified from Xenopus oocytes. The 
homologous counterparts of p90 S6 kinase in humans were soon identified and grouped 
into family of four enzymes termed as RSK1-4. It was later on observed that the RSKs may 
play a minor role in rps6 phosphorylation [1] to give way for the emergence of a major 
rps6 kinase identified as 70 kDa ribosomal S6 kinase [1–4]. The 70 kDa ribosomal S6 kinase 
was purified from mitogen stimulated Swiss mouse 3T3 cells [5]. Cloning of 70 kDa ribo-
somal S6 kinase was soon accomplished after protein sequencing of a rat and rabbit cDNA 
[6–8]. Subsequent identification and cloning of human orthologs of S6K genes RPS6KB1 
and RPS6KB2 encoding S6K1 and S6K2 thus, respectively, led to the emergence of a second 
family of S6 kinases, a principal kinase of rps6 in somatic cells [2, 9–14].
S6 kinases figure among important signaling molecules required for propagation of cell growth 
and proliferation. Adding to its importance is the fact that S6 kinase (S6K1) is a downstream 
effector of mTORC1 (mechanistic target of rapamycin), a master regulator of cell growth and 
proliferation. Evidences are strong enough to suggest that the mTOR-S6K1 axis controls fun-
damental cellular processes including transcription, translation and lipid synthesis. Further, 
this nexus partly regulates glucose homoeostasis, controls insulin sensitivity, adipocyte metab-
olism, tissue and organ size, learning, memory and aging [15]. S6K1 has therefore been consid-
ered to play a pivotal role in regulating cellular physiology. Any dysregulation of this signaling 
axis has deleterious implications ranging from metabolic disorders to various cancers. mTOR/
S6K1 signaling network has hence remained central target for various medical interventions 
employed over the years for treating the pathological conditions. However, so far the thera-
peutic interventions involving mTOR as a target molecule for treating cancers, particularly 
renal carcinomas have reported a fair share of relapses. The resistance shown to these drugs 
post chronic exposures remain one of the major concerns the scientific community is faced 
upto. One of the reasons for any such observation would be the incomplete understanding vis-
a-vis the regulation of mTOR/S6K1 axis. It is as such conceivable that improved understanding 
of S6K1 regulation would help develop novel therapeutics that should take care of these chal-
lenges. The present chapter reviews the regulation of S6K, its structure and functions.
2. S6K protein family; domain architecture and cellular localization
Based on the sequence alignment of their catalytic domains, S6Ks have been placed in AGC 
family of protein kinases that mainly comprise of protein kinase A (PKA) protein kinase G 
(PKG) and protein kinase C (PKC) [16]. The structural resemblance in AGC kinases allows 
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them to exhibit more or less a similar mode of regulation. These kinases fundamentally 
exhibit bi-lobal structural organization around the kinase domain. This structural arrange-
ment enables their amino and carboxyl termini to coordinate ATP binding [17, 18]. Further 
these kinases comprise of an activation loop (commonly known as T-loop) that precedes their 
C-terminus lobe. The phosphorylation of T-loop brings in conformational changes important 
for phosphoryl transfer. Two other important phosphorylation sites, the turn motif (TM) (so-
named due to its location at the cusp of a structural turn in the PKA tail) and hydrophobic 
motif (HM) sequentially follow the kinase domain. The phosphorylated HM site engages a 
hydrophobic pocket within the N-lobe. The phosphorylated TM site stabilizes phospho-HM 
binding to the N-lobe hydrophobic pocket. Together, these three phosphorylations stand criti-
cal in stabilizing the catalytically active state [17, 18].
RPS6KB1, human ortholog of S6K1 genes, encodes two isoforms, p70S6K1 and p85S6K1 
(formerly known as p70S6KII and p70S6KI, respectively) through alternative translational 
start sites [10]. p70S6K1, a 502 amino acid protein and its larger isoform p85S6K1, having 
nuclear localization sequence (NLS) within the 23 amino acid N-terminal extension, were 
earlier believed to remain localized in the cytoplasm and nucleus, respectively. However, 
the data generated of late, contests the nuclear localization of p85S6K1 while showing its 
sub-cellular localization to be cytoplasmic and at the same time claims p70S6K1 localiza-
tion to be both nuclear and cytoplasmic [19]. S6K2, encoded by RPS6KB2 gene, constitutes 
Figure 1. S6K isoforms, structure and domain organization with potential phosphorylating kinases along with their 
sites of action. S6K1 isoforms include p70-, p85- and p31-S6K1; alternative start site usage lengthens the p85- and p31-
S6K1 N-termini by 23 amino acids (note that p31-S6K1 lacks most of the kinase domain). S6K2 isoforms include p54- 
and p56-S6K2; alternative start site usage lengthens the p56-S6K2 N-terminus by 13 amino acids. NLSs lie within the 
N-terminal extensions of p85-S6K1 and p56-S6K2, whereas S6K2 additionally contains an NLS within the C-terminus 
as well as a proline-rich domain (Pro). S6Ks contain an acidic N-terminal domain (NTD), kinase domain (KD), linker 
region and acidic C-terminal domain (CTD). The N-terminal domain contains the TOS motif, whereas the CTD contains 
the auto-inhibitory pseudosubstrate domain and RSPRR motif. mTORC1 phosphorylates the HM (hydrophobic motif) 
site (Thr412) in the linker region and PDK1 phosphorylates the T-loop site (Thr252) within the kinase domain. Other 
regulatory phosphorylation (P) sites, including the TM (turn motif) site (Ser394), are shown.
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another member of S6 kinase family that, via alternative start sites, produces two nuclear 
isoforms, owing to the presence of nuclear localization sequence at the C-terminus [11]. 
The longer isoform, p56S6K2 comprises a 13 amino acid extension at N-terminus than its 
shorter isoform, p54S6K2 [9]. Moreover S6K2 isoforms have been characterized by the pres-
ence of proline-rich domain at the C-terminal [20]. S6K1 and S6K2 have been structur-
ally dissected into several regulatory domains, namely an acidic N-terminus that contains 
the TOR signaling (TOS) motif; the kinase domain that contains the activation/T-loop; a 
linker region that contains the TM and HM sites; and a basic C-terminus containing an 
auto-inhibitory pseudosubstrate domain (Figure 1). These proteins are homologous to each 
other within appreciable limits; their catalytic domains share about 83% identity at the 
amino acid level [9]. However, the differences observed in the extreme N- and C-terminal 
regions, direct these kinases to distinct compartments or to different molecular targets. 
Thus, for example, the C-terminal PDZ binding domain in S6K1 allows recruitment to the 
actin cytoskeleton via binding to neurabin [21] and S6K2 containing a proline-rich region in 
its C-terminus facilitates interaction with SH3 domain or WW repeat containing protein [9]. 
Besides full length forms of S6K1 and S6K2, a novel kinase domain truncated splice variant, 
p31S6K (Figure 1) with potential oncogenic properties, has also been reported [22].
3. S6 kinase regulation; a historical perspective for prevalent mode 
of activation
Research carried out over the past 20 years identified diverse growth factors and mitogens 
with the ability to activate the S6 kinases [23, 24]. Seemingly among these multiple inputs, 
insulin/IGF pathway, which signals via phosphoinositide 3-kinase (PI3K) and mTORC1 
appears to be the best studied activator of S6K1 [25, 26]. Besides PI3K, other independent 
signaling pathways like Ras/MAPK (mitogen activated protein kinase) have also been impli-
cated in S6K1 activation [27, 28]. S6K1’s contribution in controlling cell growth and prolif-
eration being paramount made the basis for studying its structure and function. The data 
accumulated over a period of time, hence revealed the molecular insights that govern activa-
tion of S6K1 by mitogens and identified, to a large extent, the complex interactions between 
its specific domains and phosphorylation sites. These observations eventually became the 
reason for putting forth the models that explain the activation of S6K1 by stepwise multi-
site phosphorylations [29–33]. These models propose that during inactive state, the basic 
C-terminal pseudosubstrate domain of S6 K1 interacts with its acidic N-terminus. This 
interaction obstructs the phosphorylation at kinase domain and renders it inactive [6, 34]. 
Stimulation by growth factors besides other mitogens result in the phosphorylation of four 
proline-directed sites at C-terminal auto-inhibitory pseudosubstrate domain (Ser434, Ser441, 
Ser444 and Ser447) [30, 32]. These phosphorylations induce a conformational change thereby 
releasing the interaction between the two termini and enables access to the HM and T-loop 
sites. Phosphorylation at these two critical sites ultimately leads to the full activation of the 
kinase [6, 34]. Several proline-directed kinases, including ERK1/2, JNK1/2 and CDK1 have 
been implicated in phosphorylation of these sites; it however remains unclear as to which 
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kinase(s) play a dominant role in-vivo [32]. Scientific observations during early 1990’s pro-
pounded the theory that mTOR controls the in-vivo activation of S6K1 [35]. These obser-
vations were further augmented during 1998–1999 when mTORC1 was shown to directly 
phosphorylate the HM site (Thr412) of S6K1 in vitro [36, 37]. The indispensible nature of 
HM site phosphorylation is further supported by the evidence that mutation of Thr 412 to 
alanine (T412A) abolishes the S6K1 activity, whereas the phosphor mimicked variant (T412E) 
enhances basal activity even in absence of mitogens [20, 33, 38]. The findings put forward 
hence strengthened the notion that phosphorylation of Thr 412 at HM site remains pivotal for 
S6K1 activation. Co-ordinate phosphorylation of Thr252 in the activation/T-loop and Thr412 
at HM site leads to maximal activation of S6K1 [29, 33, 39]. Set out to identify the potential 
kinases responsible for Thr 252 phosphorylation, in vitro followed by in-vivo studies show 
PDK1, also corroborated as a kinase for AKT, to directly phosphorylate Thr252 at T-loop 
site [29, 39, 40]. This was supported by the findings that PDK1 null embryonic stem cells, 
PDK1−/− or T252A mutation rendered S6K1 enzymatically dead [33, 41]. Further it is observed 
that PDK1 mediated phosphorylation of C-Terminus truncated variant of S6K1, S6K1-∆CT 
remains significantly higher than full length S6K1 while mutation in c-terminal phosphory-
lation sites to alanine results in poor S6K1 activation [29]. Moreover, PDK1 poorly activates 
S6K1 T412A-∆CT or T394A-∆CT in vitro. All these findings reveal that unphosphorylated 
c-terminus puts restraint toward full activation of S6K1 by blocking the access of PDK1 to 
activation loop and the importance of HM and TM sites toward bringing PDK1 mediated 
S6K1 activation [29]. Phosphorylation of Ser394 (or Ser371 in P70S6K isoform) at turn motif 
site also remains of much significance for complete activation of S6K1, as S394A substitu-
tion of S6K1 renders it completely inactive [42]. Notwithstanding the importance of turn 
motif site, the data accumulated on regulation and function of this phosphorylation event 
has progressed, albeit rather slowly. Whatever little the quantum of data may be available for 
regulation around TM site phosphorylation till date, it concordantly reflects that this site does 
not represent an autophosphorylation event [42]. Some more interesting observations reveal 
that even the addition of T412E substitution fails to restore the activity of S394A mutant, thus 
supporting the notion that this site plays an important yet independent role in regulating the 
activity of S6K1 [42]. Evidences, though scant, have also emerged which corroborate mTOR 
in promoting Ser394 phosphorylation in vitro [43]. However, since data accumulated in cer-
tain other cases does not correlate phospho-Ser394 well with mTORC1 activity, intermedia-
tion of some other kinase besides mTORC1 is also speculated. Reports based on analogy to 
co-translational phosphorylation of TM site (Thr450) in AKT are tempting to speculate that 
S6K1 TM site phosphorylation also represents an early event that occurs co-translationally 
prior to T-loop and HM site phosphorylation [44]. Indeed, a recent report supports such an 
idea, as Ser394 phosphorylation occurs simultaneously with the production of S6K1 pro-
tein from a transfected plasmid [31]. Since the phosphorylations at the HM and T-loop sites 
exhibit strong cooperativity, the temporal order of these two phosphorylations has not yet 
been convincingly deciphered. However, the data available till date has put forth two models 
for S6K1 activation wherein the conventional and widely accepted model suggests mTORC1 
mediated phosphorylation at Thr 412 to precede PDK1 mediated phosphorylation at Thr 252 
[29, 38, 39]. An alternate model however, suggests that the phosphorylation at T-loop (Thr 
252) precedes HM phosphorylation (Thr 412) [31, 33] (Figure 2).
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S6K1 amino terminus serves a regulatory role in promoting phosphorylation at HM site and 
thereby at T-loop site that ultimately brings about its complete activation. The regulation by 
amino terminus is documented to be two pronged. Firstly, it acts as a receptor of an activat-
ing input critical for Thr 412 and Thr 252 phosphorylation; and, secondly, it suppresses an 
inhibitory function mediated by C-terminus. These observations have strong scientific sup-
port as the data generated over a period of time shows that amino terminus truncation of 
S6K1 (∆NT) abolishes the phosphorylation of rapamycin-sensitive sites Thr 412, Thr 252, Ser 
427 and renders it inactive [38, 45] whereas additional deletion of C-terminus (∆NT/∆CT) 
restores all the rapamycin-sensitive phosphorylations as well as the kinase activity of S6K1.
The regulatory function of the amino terminus was mapped to a short stretch of amino acids 
(comprising of 5–9 amino acids and represented by a signature sequence FDIDL) present at 
extreme end known as TOS motif [20]. It has been shown that S6K1 truncated of TOS motif 
or its F5A variant (F5A mutation within the FDIDL sequence) abolishes S6K1 kinase activ-
ity as well as Thr412 and Thr252 phosphorylation. However, deletion of C-terminus from 
the F5A mutant (F5A-∆CT) partially restores kinase activity and Thr 412 phosphorylation 
[20]. The TOS motif function has been related toward a launch pad required for mTORC1 
to engage substrates and to mediate phosphorylation of rapamycin-sensitive sites [46, 47]. 
The data generated supports the view that mTOR interaction with TOS motif is indirect and 
Figure 2. Stepwise activation of S6K1 via multi-site phosphorylation. Conventional model: the interaction of the C- and 
N-terminal domains results in auto-inhibition of S6K1. Step 1: mitogens promote C-terminal domain (C) phosphorylation 
on multiple sites to induce a more relaxed conformation. Step 2: the release of the auto-inhibitory C-terminal domain 
(CTD) enables mTORC1 access to the HM and thus phosphorylation of Thr412. Step 3: the release of the auto-inhibitory 
CTD and phosphorylation on Thr412 enables PDK1-mediated phosphorylation of the T-loop on Thr252, resulting in full 
activation of S6K1. Phospho-Thr412 serves as docking site for PDK1. Owing to insufficient data, the temporal order of TM 
site phosphorylation (Ser394) is not depicted. Alternative model: Step 1: an unknown kinase phosphorylates the inactive 
form of S6K on the TM site Ser394. Step 2: mitogens promote C-terminal domain (C) phosphorylation on multiple sites to 
induce a more relaxed conformation. Step 3: The release of the auto-inhibitory C-terminal domain enables PDK1 access 
to the T-loop. Step 4: PDK1-mediated phosphorylation of Thr252 promotes mTORC1-mediated phosphorylation on the 
HM site, Thr412. KD, kinase domain; N,N-terminal domain.
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mediated by another member of mTORC1 complex, a scaffold protein called Raptor [46, 47]. 
For phosphorylation of S6K1 and 4EBP-1, the other mTORC1 effector molecule, binding 
with raptor has been unequivocally stated to be critical. However, the precise mechanism 
by which raptor mediates efficient phosphorylation of S6K1 and 4EBP-1 remains largely 
debatable. Two models have however been proposed to explain this mechanism. The first 
model suggests that raptor and mTOR associate in two states with varying affinities gov-
erned by the nutrient availability. During nutrient starved state Raptor binds tightly to 
mTOR and renders it inactive. While as the loose-binding complex, formed during nutrient 
sufficiency, activates mTOR and promotes efficient phosphorylation of mTOR targets [48]. 
Furthermore, overexpression of raptor increases the amount of mTOR found in the tight-
binding complex, thereby explaining the observation that overexpression of raptor inhib-
its mTOR activity. However, it is interesting to note that rapamycin is able to disrupt the 
raptor-mTOR interaction regardless of nutrient status [49], but it is phosphate dependent. 
The second model supports the existence of Raptor as a scaffolding protein for mTORC-
1complex, wherein Raptor has been shown to preferentially bind unphosphorylated forms 
of mTOR targets and recruit the substrates to the mTOR complex for phosphorylation. Role 
of S6K1 amino terminus in suppressing the inhibitory function of C-terminus remained 
unclear till identification of an RSPRR motif (a short stretch of 5 amino acids, 433–437) in 
C-terminus way back in 2005 [47]. This motif has been suggested to negatively regulate 
S6K1 activation. Evidences, though scant, have propounded that RSPRR motif functions 
as a docking site for a negative regulator, such as a phosphatase, that is suppressed by 
mTORC1 [47].R3Amutation of RSPRR motif within the dead ∆NT or TOS motif-mutant 
(F5A) backbone (NT-R3A or F5A-R3A) has been shown to rescue insulin-stimulated Thr412 
phosphorylation and S6K1 activation [15]. These findings though place TOS motif in exhib-
iting negative control over RSPPR motif inhibition, the exact mechanism behind this regula-
tion still remains largely a mystery.
3.1. Rapamycin, S6K1 inhibition; a chronology of events
In 1970s, a bacterial strain, Streptomyces hygroscopicus was isolated from a soil sample from 
Easter Island (“Rapa Nui” in the native language) [50]. This strain was found to produce an 
anti-fungal metabolite [51]. Post purifications, the metabolite was characterized as a macrocy-
clic lactone and named “Rapamycin” after its birthplace (Figure 3) [52].
The strong ability of rapamycin to modulate cellular proliferation besides its promising role 
in immune suppression for treating various cancers lead to a desperate search in decoding 
its mode of action and simultaneously initiated hunt for nailing down its targets. The search 
continued for about two decades and finally culminated in early 1990s with identification of 
a target protein in yeast, whose mutant conferred resistance to the growth inhibitory effects 
of rapamycin. The protein was subsequently named as TOR (target of rapamycin) [53–56]. 
Shortly after, the mammalian counterpart of TOR (mTOR) was identified as physical target of 
rapamycin by three groups separately in 1994, 1995, respectively [57–59]. However effective 
mechanism of rapamycin action remained oblivious till intracellular cofactor, the peptidyl-
prolyl cis/trans isomerase, immunophilin FK506-binding protein 12 (FKBP12) was shown to 
bind rapamycin as a gain-of-function component to mediate its inhibitory effect on TOR [56]. 
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Thus, TOR is also referred to as FKBP12 rapamycin associated protein (FRAP) [60].Rapamycin-
FKBP12 complex binds to the FKBP12-rapamycin binding (FRB) domain of TOR (Figure 4) [55, 
60–62] to inhibit its intrinsic kinase activity, including autophosphorylation, thereby inhibiting 
access of TOR to its substrates [56]. This finding is however in contradiction with the earlier 
reports wherein it was shown that rapamycin has little effect on mTOR kinase activity [63]. In 
mammals, rapamycin in complex with FKBP12 acts as an allosteric inhibitor of mTOR com-
plex1 (mTORC1). Only mTORC1 is acutely sensitive to inhibition of rapamycin. However, long 
term exposure to rapamycin has been shown to inhibit mTORC2 in certain cell types [64]. It is 
believed that the rapamycin-FKBP12 complex prevents the association between mTOR and rap-
tor; therefore, downstream targets that depend on raptor binding are specifically inhibited [49]. 
Figure 3. Electron-density model of a molecule of the immunosuppressant drug rapamycin: It is mainly used to prevent 
rejection in organ transplantation, and is used in kidney transplants. It also has anti-fungal and anti-cancer properties, 
and was originally derived from soil bacteria found on Easter Island. The chemical formula is C51.H79.N.O13. The atoms 
are represented here as color-coded blobs: carbon (green), hydrogen (white), nitrogen (blue) and oxygen (red) (adapted 
from Dr. Tim Evans Science photo library).
Figure 4. Association of rapamycin with TOR: schematic representation of structural organization of mTOR at domain 
level and its association with rapamycin–FKBP12 complex.
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S6K1 being a downstream effector of mTOR, shows inhibitory response to rapamycin as is 
evidenced by loss of its ability to phosphorylate its substrate, ribosomal protein S6.
Early 1990s witnessed a rigorous search for identifying the rapamycin-sensitive regulatory 
phosphorylation sites in S6K1 and during 1995 three sites, T252 in the activation/T-loop, 
T412 in hydrophobic motif and S427 in the linker domain, which connects the auto-inhibi-
tory domain to the catalytic domain were identified as principal rapamycin-sensitive sites 
[65]. These sites were shown to be dephosphorylated by rapamycin in hierarchical fashion 
T412 > S427 > T252 with T412 dephosphorylation most closely paralleling loss of kinase activ-
ity [65]. Besides, these sites were shown to be responsive to mitogenic stimulation as well 
[66]. Though all these three sites show rapamycin responsiveness, their conversions to either 
acidic or neutral amino acids reveal that T252 and T412 were critical regulatory sites where 
as T427 appeared to play a modulatory function [65]. Further T412 was shown to be principal 
site of rapamycin-induced S6K1 inactivation as T412E showed increased basal activity and 
was largely rapamycin resistant [65]. In 1995, Weng et al. reported the cooperativity among 
the two termini for exhibiting their regulatory effects on S6K1 activation by showing that 
amino- terminus truncated mutant, S6K1-∆NT, was inactive. However, additional deletion 
of carboxy terminus, generating S6K1-∆NT/∆CT, rescued its phosphorylation and activation 
state. Surprisingly it was observed that the mutant was rapamycin resistant [45]. However, its 
responsiveness toward Wortmannin inhibition did not get compromised. These observations 
combined with the findings that the carboxy-terminal truncated S6K1 (S6K1-∆CT) retains 
rapamycin sensitivity raised the speculations during latter half of 1990’s that the inhibitory 
effect of the rapamycin–FKBP12 complex on S6K1 was either due to blockade of an upstream 
activator or activation of some phosphatase which mediate their influence through the two 
termini. The presence of Thr412 phosphorylation on S6K1-∆NT/∆CT isolated from rapamycin-
treated cells questioned the idea that mTORC1 represents the sole S6K1 Thr412 kinase. In 
∆NT/∆CT, serum and insulin promote Thr412 phosphorylation and kinase activation in a com-
pletely rapamycin-resistant manner, suggesting that a rapamycin-insensitive kinase mediates 
Thr412 phosphorylation [38, 45]. This conundrum was soon resolved in 2005 by observing that 
rapamycin-insensitive mTORC2 mediates non-physiological S6K1 Thr412 phosphorylation in 
S6K1 mutants lacking a C-terminus [67]. It was also observed that unlike other AGC kinases 
S6Ks have atypically an extended C-terminus that imposes additional inhibitory influence on 
their state of activity [15]. Hence in the dead ∆NT allele, mTORC1 (mTOR/raptor) cannot dock 
to S6K1 and as such is incapacitated to phosphorylate Thr412, and mTORC2 (mTOR/rictor) 
cannot phosphorylate Thr412 due to steric hindrance imposed by the extended C-terminus 
[67]. In the partially rapamycin-resistant ∆CT mutant, both rapamycin-sensitive mTORC1 and 
rapamycin-insensitive mTORC2 cooperatively mediate Thr412 phosphorylation. In ∆NT/∆CT 
(and F5A-∆CT), only rapamycin-insensitive mTORC2 mediates Thr412 phosphorylation.
4. Other modes of S6K1 regulation
Studies of late propose the involvement of various post translational modifications (PTMs) in 
regulation of S6K1. Prominent among them are phosphatase-mediated dephosphorylation, 
acetylation and ubiquitination.




S6K1 has been proposed to be regulated by co-ordinated action of phosphatases. This was 
observed while examining the action of rapamycin on phosphorylation state of S6K1.Whereas 
as rapamycin could dephosphorylate S6K1 through its inhibitory action on mTORC1 complex; 
the involvement of certain phosphatases to regulate this event was not ruled out. Indeed, S6Ks 
have been suspected to represent targets of PP2A (protein phosphatase 2A)-like phosphatases. 
This is supported by the evidence that regulation of several TOR substrates in S. cerevisiae  
occurs via suppression of PP2A-like phosphatases [68]. Further it has also been shown that 
PP2A interacts with wild type S6K1 and not ∆NT/∆CT S6K1, a variant truncated of both the 
termini [69]. It is of late been observed that genetic ablation of PP2A regulatory subunit B 
(PP2A-B′) in Drosophila melanogaster leads to dS6K (Drosophila S6K) deregulation and a vari-
ety of metabolic defects [70]. Some further studies report that S6K1 phosphorylation (412) is 
enhanced in human cells upon knock down of PPP2R5C, the human PP2A-B′ orthologue [70]. 
All these studies support the role of phosphatases in regulating S6K1 activity. However, it 
is to be ascertained how mTOR influences these PP2A like phosphatase to modulate S6K1 
Thr412 phosphorylation.
4.2. Acetylation and ubiquitination
Acetylation of S6K1 occurs reportedly by the action of two acetyltransferase enzymes, p300/
CBP (cAMP-response-element-binding protein binding protein) and PCAF (p300/CBP-
associated factor) [71].While as this PTM has been shown to occur on extreme C-terminus of 
S6K1 in response to the stimulation by mitogens, its dependence on phosphorylation has not 
been confirmed [72]. Acetylation has been primarily linked to the stabilization of S6K1 [71]. 
However, the concrete evidence to support this notion has remained largely elusive till date.
Polyubiquitination is another PTM, S6K1 is responsive to. S6K1 appears to experience the 
ubiquitination in response to mitogen stimulation [73, 74] through direct action of ubiquitin 
ligase, ROC1 [75]. RNA interference (RNAi) mediated knock down of ROC1 results in stabili-
zation of S6K. These results are hence suggestive of the notion that polyubiquitination causes 
destabilization of S6K1 and a resultant attenuation of S6K1 downstream signals. Although 
regulation of S6K1 through ubiquitination still remains in its infancy; it however has opened 
a new window toward understanding detailed mechanistic inputs of proteasome mediated 
S6K1 regulation and function.
5. Functions associated with S6K1—a debatable discourse
S6K1, a downstream effector of mTOR is considered to be a multifaceted effector that regu-
lates cell growth and proliferation by phosphorylating multiple ways. To add to its wide 
range of functions, S6K1 has much recently been shown to play a pivotal role in cellular 
senescence through its newly found substrate ZRF1 [76]. S6K1 gets activated in response to 
various signaling pathways including mTOR, PI3-kinase and MAPK, in a coordinated man-
ner through sequential phosphorylation events directed at multiple sites [62]. While S6K1 
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extends its influence on various cellular functions, some of its associated functions still appear 
untenable, reason being the inadequate support data. Some of the S6K1 associated functions 
are briefly described below:
5.1. Cell growth and translational control—what is the connection?
S6K1 has been shown to control cell growth primarily by its ability to phosphorylate S6 pro-
tein of 40S ribosomal subunit (rpS6). These phosphorylations are shown to be localized at the 
C-terminus and happen in sequential order, namely S236 > S235 > S240 > S244 > S247. The 
dependence of S6 phosphorylation on S6K1 can traced by the observation that rpS6 deficient 
mice, rps6−/− show phenotypic resemblance to S6K1 deficient mice, S6K1−/−. Although these 
mice are viable and fertile, however both exhibit cell growth defects. It however is confusing 
to observe that S6K1−/− mice display minimal defects in rpS6 phosphorylation, while S6 K2, 
homolog of S6K1, deficient mice, that is, S6K2−/− grow to normal size despite exhibiting a 
significant reduction in rpS6 phosphorylation [77]. The conundrum can partly be resolved by 
the observation that claims selective recruitment of S6K1 and S6K2 to different cellular com-
partments and as such enables them to differentially phosphorylate rpS6 or alternatively by 
the preposition that rpS6 phosphorylation may ensue at a specific developmental stage where 
S6K1 but not S6K2 is active. Although a discordance seems to appear vis-a-vis S6K1 activa-
tion, rpS6 phosphorylation and cell growth, their complete understanding as far as thera-
peutics is concerned remains but pivotal. Although S6 phosphorylation was initially thought 
to be required for selectively translating mRNAs characterized by 5′-oligo Pyrimidine tract 
(5’-TOP). Later studies however confirmed that 5’ TOP mRNA translation remains unaffected 
in S6K1−/−/S6K2−/− mice, which display minimal rpS6 phosphorylation [77], hence suggesting 
these two events to be independent [78].
S6K1 maintains its influence on cellular translation not only by the ability to phosphorylate 
ribosomal protein S6 (rpS6) but some studies provide evidences to establish S6K1 as a tran-
scription factor kinase as well. One of the study shows S6K1 to phosphorylate eukaryotic 
initiation factor 4B (eIF4B), a component of cap-binding complex to control cap dependent 
translation. While as inactive S6K1 associates with eIF3 (a component of pre-initiation com-
plex) and upon activation by mTORC1, via serum stimulation, dissociates to phosphory-
late eIF4B, another component of pre-initiation complex [79, 80]. Besides it also controls 
translational initiation by phosphorylating PDCD4, a negative regulator of eIF4A (Figure 5). 
Phosphorylated PDCD4 gets ultimately degraded by ubiquitin ligase βTRCP [81]. The impor-
tance of S6K1 vis-a-vis translational control can further be demonstrated by the observation 
which implicates S6K1 in controlling translation elongation as well. The study carried shows 
S6K1 to phosphorylate and inactivate eEF2k (eukaryotic elongation factor-2 kinase, a negative 
regulator of translation [82].
5.2. Cell cycle progression-a reality check
S6K1 has been extensively discussed as a kinase that drives cells from G1 to S phase during cell 
cycle progress. However, the data in support does not seem to match this notion completely 
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and in fact some of the data available even contests the veracity of these claims. Whereas 
Embryonic Stem (ES) cells devoid of S6K1 (S6K1−/−) and mouse embryonic fibroblasts (MEFs) 
obtained from S6K1 deficient mice do not show significant defects in cell proliferation [77], 
other studies implicate S6K1 in facilitating cell cycle progression through phosphorylation of 
estrogen receptor leading to the activation of its target genes that ultimately promotes cellular 
proliferation [83]. Additionally S6K1 exerts its control over cellular transcription through its 
ability to phosphorylate cAMP response element binding protein (CREB) isoform CREMr and 
transcription factor UBF-1 [84]. Phosphorylated UBF-1 in turn activates RNA Polymerase 1 
driven transcription of genes encoding ribosomal RNAs and as such aid in ribosomal biogen-
esis. However, contrary to this belief McMullen et al. proposed no absolute requirement of 
S6K at either transcriptional or translational levels during ribosomal biogenesis. They showed 
that S6K−/− mice do not exhibit impaired cardiac hypertrophy, a response dependent on ribo-
somal biogenesis [85]. These observations put a question mark on the actual involvement of 
S6K1 in controlling cell cycle progression. Howsoever discordant the views with respect to 
direct involvement of S6K1 may be but the role of S6K1 in accelerating the cell cycle from G1 
to S remains undisputed.
5.3. Cellular metastasis—handy option for therapeutic interventions
S6 kinase, being a downstream effector of mTOR is upregulated in various cancerous situa-
tions and as such regulates cellular metastasis. Its involvement in brain tumor pathogenesis 
was established by the fact that mTOR/S6K axis remains constitutively activated in glioma 
cells and upon S6K knockdown, the transformed phenotype of these cells is partially res-
cued [86]. Additionally constitutive activation of S6K1 has been reported in esophageal 
squamous cell carcinomas (ESCC) [87]. These and several other examples highlight the 
importance of S6K1 in various cancerous state and as such makes it a potential target for 
therapeutic interventions to treat cancer. A number of pharmaceutical companies have 
Figure 5. S6K1, a component of translation initiation complex: S6K1 is bound to eIF3 in basal (resting) state cells. Upon 
serum stimulation, mTORC1 is recruited to the complex, wherein it activates S6K1, which dissociates from eIF3 and 
phosphorylates several of its targets involved in the initiation of translation.
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already ventured in developing S6K specific inhibitors like ATP-competitive compounds 
that exhibit selective inhibition of S6K. This remains important in the backdrop of can-
cer relapses/resistance observed while treating them with mTOR inhibitor rapamycin or 
its rapalogues [88]. However, until recently it was not clear as to what contributes to the 
rapamycin resistance in these cells. This conundrum was to a greater extent resolved when 
MAPK interacting kinase (MNK) was found to be an active player in exerting rapamycin 
resistance in cancer cells. The study deliberated that cancer cell resistance to the mTORC1 
inhibitor rapamycin involves MNK activation via a feedback signaling loop elicited by 
rapamycin [89, 90]. Much recently a study by Brown et al. reveals that post rapamycin 
treatment mTORC1 activity is sustained by MNK in cancer cells by way of promoting the 
association between MNK and mTORC1 to form a sub-complex. This way MNK facilitates 
binding of mTORC1 with its substrates and with phosphatidyl inositol 3’kinase-related 
kinase (PIKK) stabilizer, TELO2, while discouraging DEPTOR (endogenous mTOR inhibi-
tor) binding [91]. In addition MNKs are also known for phosphorylating eukaryotic initia-
tion factor 4E, eIF4e [92] and as such may play a role in cellular translation. Further the data 
generated in our lab hints out at the possible role of eIF4e in regulating S6K1 (unpublished 
data). We believe that prolonged exposure of cells to rapamycin results in activation of 
MNKs with the resultant activation of eIF4e. As a result S6K1 gets activated to counter the 
anti-proliferative/anti-cancerous effects of rapamycin (Figure 6). Thus therapeutic inter-
ventions envisaging S6K1 as a direct target would help overcome, to a larger extent, the 
resistance experienced toward mTORC1 inhibitors and as such emerge as more appropriate 
target for treating cancers.
Figure 6. S6K1, a prudent target for treating cancers: an illustration representing S6K1 as a potential target for the 
specific inhibitors which could be used to overcome the resistance observed while using mTORC1 inhibitors during 
various cancerous situations.




Understanding S6K1 regulation and its associated functions over the last two decades has seen an 
upward trend. It has now been possible to establish S6K1 an important regulator of cell growth 
and proliferation. Further our understanding vis-à-vis S6K1 functions have also improved con-
siderably to dissociate many of its functions from the ones related to phosphorylating rpS6 only. 
Instead its control over various cellular factors makes it more important candidate for regulating 
cellular physiology. Of late, S6K1 appears as a prudent target for treating various cancers and 
as such various trials have been initiated to use specific S6K1 inhibitors with the aim to treat 
different cancers where the routine practices of using generalized drugs appear less effective. 
However, achieving a complete success in this endeavor still seems difficult. A major challenge in 
this regard is to ensure that S6K1 s role is tumor specific regardless of its type or origin. Resolving 
such issues will of course be a task that would attract more research in the years to come.
Conflict of interest
The authors declare that there is no conflict of interest.
Author details
Sheikh Tahir Majeed1, Rabiya Majeed1,2, Ghazia Shah1 and Khurshid I Andrabi1*
*Address all correspondence to: andrabik@uok.edu.in
1 Department of Biotechnology, Science block, University of Kashmir, Jammu and Kashmir, 
India
2 Department of Biochemistry, University of Kashmir, Jammu and Kashmir, India
References
[1] Anjum R, Blenis J. The RSK family of kinases: Emerging roles in cellular signalling. Nature 
Reviews. Molecular Cell Biology. 2008;9(10):747
[2] Chung J, Kuo CJ, Crabtree GR, Blenis J. Rapamycin-FKBP specifically blocks growth-
dependent activation of and signaling by the 70 kd S6 protein kinases. Cell. 1992;69(7): 
1227-1236
[3] Price DJ, Calvo V, Avruch J, Bierer BE. Rapamycin-induced inhibition of the 70-kilodal-
ton S6 protein kinase. Science. 1992;257(5072):973-977
[4] Stewart MJ, Berry CO, Zilberman F, Thomas G, Kozma SC. The Drosophila p70s6k homo-
log exhibits conserved regulatory elements and rapamycin sensitivity. Proceedings of 
the National Academy of Sciences. 1996;93(20):10791-10796
Homeostasis - An Integrated Vision156
[5] Jenö P, Ballou LM, Novak-Hofer I, Thomas G. Identification and characterization 
of a mitogen-activated S6 kinase. Proceedings of the National Academy of Sciences. 
1988;85(2):406-410
[6] Banerjee P, Ahmad MF, Grove JR, Kozlosky C, Price DJ, Avruch J. Molecular structure of 
a major insulin/mitogen-activated 70-kDa S6 protein kinase. Proceedings of the National 
Academy of Sciences. 1990;87(21):8550-8554
[7] Harmann B, Kilimann MW. cDNA encoding a 59 kDa homolog of ribosomal protein S6 
kinase from rabbit liver. FEBS Letters. 1990;273(1-2):248-252
[8] Kozma SC, Ferrari S, Bassand P, Siegmann M, Totty N, Thomas G. Cloning of the mito-
gen-activated S6 kinase from rat liver reveals an enzyme of the second messenger sub-
family. Proceedings of the National Academy of Sciences. 1990;87(19):7365-7369
[9] Gout I, Minami T, Hara K, Tsujishita Y, Filonenko V, Waterfield MD, et al. Molecular 
cloning and characterization of a novel p70 S6 kinase, p70 S6 kinase β containing a pro-
line-rich region. The Journal of Biological Chemistry. 1998;273(46):30061-30064
[10] Grove JR, Banerjee P, Balasubramanyam A, Coffer PJ, Price DJ, Avruch J, et al. Cloning 
and expression of two human p70 S6 kinase polypeptides differing only at their amino 
termini. Molecular and Cellular Biology. 1991;11(11):5541-5550
[11] Koh H, Jee K, Lee B, Kim J, Kim D, Yun Y-H, et al. Cloning and characterization of 
a nuclear S6 kinase, S6 kinase-related kinase (SRK); a novel nuclear target of Akt. 
Oncogene. 1999;18(36):5115
[12] Lee-Fruman KK, Kuo CJ, Lippincott J, Terada N, Blenis J. Characterization of S6K2, a 
novel kinase homologous to S6K1. Oncogene. 1999 Sep;18(36):5108-5114
[13] Saitoh M, Ten Dijke P, Miyazono K, Ichijo H. Cloning and characterization of 
p70S6KβDefines a novel family of p70 S6 kinases. Biochemical and Biophysical Research 
Communications. 1998;253(2):470-476
[14] Shima H, Pende M, Chen Y, Fumagalli S, Thomas G, Kozma SC. Disruption of the 
p70s6k/p85s6k gene reveals a small mouse phenotype and a new functional S6 kinase. 
The EMBO Journal. 1998;17(22):6649-6659
[15] Magnuson B, Ekim B, Fingar DC. Regulation and function of ribosomal protein S6 kinase 
(S6K) within mTOR signalling networks. The Biochemical Journal. 2012;441(1):1-21
[16] Hanks SK, Hunter T. Protein kinases 6. The eukaryotic protein kinase superfamily: Kinase 
(catalytic) domain structure and classification. The FASEB Journal. 1995;9(8):576-596
[17] Jacinto E, Lorberg A. TOR regulation of AGC kinases in yeast and mammals. The 
Biochemical Journal. 2008;410(1):19-37
[18] Pearce LR, Komander D, Alessi DR. The nuts and bolts of AGC protein kinases. Nature 
Reviews. Molecular Cell Biology. 2010;11(1):9
[19] Rosner M, Hengstschläger M. Nucleocytoplasmic localization of p70 S6K1, but not of its 
isoforms p85 and p31, is regulated by TSC2/mTOR. Oncogene. 2011;30(44):4509
S6 Kinase: A Compelling Prospect for Therapeutic Interventions
http://dx.doi.org/10.5772/intechopen.75209
157
[20] Schalm SS, Blenis J. Identification of a conserved motif required for mTOR signaling. 
Current Biology. 2002;12(8):632-639
[21] Burnett PE, Blackshaw S, Lai MM, Qureshi IA, Burnett AF, Sabatini DM, et al. Neurabin 
is a synaptic protein linking p70 S6 kinase and the neuronal cytoskeleton. Proceedings 
of the National Academy of Sciences. 1998;95(14):8351-8356
[22] Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the 
splicing factor SF2/ASF is a proto-oncogene. Nature Structural & Molecular Biology. 
2007;14(3):185
[23] Fenton TR, Gout IT. Functions and regulation of the 70 kDa ribosomal S6 kinases. The 
International Journal of Biochemistry & Cell Biology. 2011;43(1):47-59
[24] Meyuhas O, Dreazen A. Ribosomal protein S6 kinase: From TOP mRNAs to cell size. 
Progress in Molecular Biology and Translational Science. 2009;90:109-153
[25] Foster KG, Fingar DC. Mammalian target of rapamycin (mTOR): Conducting the cellu-
lar signaling symphony. The Journal of Biological Chemistry. 2010;285(19):14071-14077
[26] Zoncu R, Efeyan A, Sabatini DM. mTOR: From growth signal integration to cancer, dia-
betes and ageing. Nature Reviews. Molecular Cell Biology. 2011;12(1):21
[27] Chou MM, Blenis J. The 70 kDa S6 kinase complexes with and is activated by the rho 
family G proteins Cdc42 and Rac1. Cell. 1996;85(4):573-583
[28] Romanelli A, Martin KA, Toker A, Blenis J. p70 S6 kinase is regulated by protein kinase 
Cζ and participates in a phosphoinositide 3-kinase-regulated signalling complex. 
Molecular and Cellular Biology. 1999;19(4):2921-2928
[29] Alessi DR, Kozlowski MT, Weng Q-P, Morrice N, Avruch J. 3-Phosphoinositide-
dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase 
in vivo and in vitro. Current Biology. 1998 Jan 15;8(2):69-81
[30] Ferrari S, Bannwarth W, Morley SJ, Totty NF, Thomas G. Activation of p70s6k is asso-
ciated with phosphorylation of four clustered sites displaying Ser/Thr-Pro motifs. 
Proceedings of the National Academy of Sciences. 1992;89(15):7282-7286
[31] Keshwani MM, Von Daake S, Newton AC, Harris TK, Taylor SS. Hydrophobic motif 
phosphorylation is not required for activation loop phosphorylation of p70 ribosomal 
protein S6 kinase 1 (S6K1). The Journal of Biological Chemistry. 2011;286(26):23552-23558
[32] Mukhopadhyay NK, Price DJ, Kyriakis JM, Pelech S, Sanghera J, Avruch J. An array of 
insulin-activated, proline-directed serine/threonine protein kinases phosphorylate the 
p70 S6 kinase. The Journal of Biological Chemistry. 1992;267(5):3325-3335
[33] Weng Q-P, Kozlowski M, Belham C, Zhang A, Comb MJ, Avruch J. Regulation of the p70 
S6 kinase by phosphorylation in vivo analysis using site-specific anti-phosphopeptide 
antibodies. The Journal of Biological Chemistry. 1998;273(26):16621-16629
[34] Price DJ, Mukhopadhyay NK, Avruch J. Insulin-activated protein kinases phosphory-
late a pseudosubstrate synthetic peptide inhibitor of the p70 S6 kinase. The Journal of 
Biological Chemistry. 1991;266(25):16281-16284
Homeostasis - An Integrated Vision158
[35] Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL. Control of p70 s6 kinase by 
kinase activity of FRAP in vivo. Nature. 1995;377(6548):441
[36] Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM. RAFT1 phosphorylation 
of the translational regulators p70 S6 kinase and 4E-BP1. Proceedings of the National 
Academy of Sciences. 1998;95(4):1432-1437
[37] Isotani S, Hara K, Tokunaga C, Inoue H, Avruch J, Yonezawa K. Immunopurified mam-
malian target of rapamycin phosphorylates and activates p70 S6 kinase α in vitro. The 
Journal of Biological Chemistry. 1999;274(48):34493-34498
[38] Dennis PB, Pullen N, Pearson RB, Kozma SC, Thomas G. Phosphorylation sites in the 
autoinhibitory domain participate in p70s6k activation loop phosphorylation. The 
Journal of Biological Chemistry. 1998;273(24):14845-14852
[39] Pullen N, Dennis PB, Andjelkovic M, Dufner A, Kozma SC, Hemmings BA, et al. 
Phosphorylation and activation of p70s6k by PDK1. Science. 1998;279(5351):707-710
[40] Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PRJ, Reese CB, et al. Character-
ization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and 
activates protein kinase Bα. Current Biology. 1997 Apr 1;7(4):261-269
[41] Williams MR, Arthur JSC, Balendran A, van der Kaay J, Poli V, Cohen P, et al. The role 
of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in 
embryonic stem cells. Current Biology. 2000;10(8):439-448
[42] Moser BA, Dennis PB, Pullen N, Pearson RB, Williamson NA, Wettenhall RE, et al. 
Dual requirement for a newly identified phosphorylation site in p70s6k. Molecular and 
Cellular Biology. 1997;17(9):5648-5655
[43] Saitoh M, Pullen N, Brennan P, Cantrell D, Dennis PB, Thomas G. Regulation of an acti-
vated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphoryla-
tion site. The Journal of Biological Chemistry. 2002;277(22):20104-20112
[44] Oh WJ, Wu C, Kim SJ, Facchinetti V, Julien L-A, Finlan M, et al. mTORC2 can associate 
with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt 
polypeptide. The EMBO Journal. 2010;29(23):3939-3951
[45] Cheatham L, Monfar M, Chou MM, Blenis J. Structural and functional analysis of 
pp70S6k. Proceedings of the National Academy of Sciences. 1995;92(25):11696-11700
[46] Nojima H, Tokunaga C, Eguchi S, Oshiro N, Hidayat S, Yoshino K, et al. The mam-
malian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 
kinase and 4E-BP1 through their TOR signaling (TOS) motif. The Journal of Biological 
Chemistry. 2003;278(18):15461-15464
[47] Schalm SS, Tee AR, Blenis J. Characterization of a conserved C-terminal motif (RSPRR) 
in ribosomal protein S6 kinase 1 required for its mammalian target of rapamycin-depen-
dent regulation. The Journal of Biological Chemistry. 2005;280(12):11101-11106
[48] Lee C-H, Inoki K, Guan K-L. mTOR pathway as a target in tissue hypertrophy. Annual 
Review of Pharmacology and Toxicology. 2007;47:443-467
S6 Kinase: A Compelling Prospect for Therapeutic Interventions
http://dx.doi.org/10.5772/intechopen.75209
159
[49] Kim D-H, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, et al. mTOR 
interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth 
machinery. Cell. 2002;110(2):163-175
[50] Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22, 989), a new antifungal antibiotic. 
Journal of Antibiotics (Tokyo). 1975;28(10):721-726
[51] Sehgal SN, Baker H, Vézina C. Rapamycin (AY-22, 989), a new antifungal antibiotic. 
Journal of Antibiotics (Tokyo). 1975;28(10):727-732
[52] Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with 
rapamycin derivatives. Annals of Oncology. 2005;16(4):525-537
[53] Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant 
rapamycin in yeast. Science. 1991;253(5022):905-909
[54] Kunz J, Henriquez R, Schneider U, Deuter-Reinhard M, Movva NR, Hall MN. Target of 
rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required 
for G1 progression. Cell. 1993;73(3):585-596
[55] Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N. mTOR signaling: 
Implications for cancer and anticancer therapy. British Journal of Cancer. 2006;94(2):195
[56] Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 
2006;124(3):471-484
[57] Brown EJ, Albers MW, Shin TB, Keith CT, Lane WS, Schreiber SL. A mammalian protein 
targeted by G1-arresting rapamycin–receptor complex. Nature. 1994;369(6483):756
[58] Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: A mamma-
lian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous 
to yeast TORs. Cell. 1994;78(1):35-43
[59] Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, et al. Isolation 
of a protein target of the FKBP12-rapamycin complex in mammalian cells. The Journal of 
Biological Chemistry. 1995;270(2):815-822
[60] Fingar DC, Blenis J. Target of rapamycin (TOR): An integrator of nutrient and growth 
factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 
2004;23(18):3151
[61] Gingras A-C, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/
mTOR. Genes & Development. 2001;15(7):807-826
[62] Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000;103(2):253-262
[63] Peterson RT, Beal PA, Comb MJ, Schreiber SL. FKBP12-rapamycin-associated protein 
(FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. 
The Journal of Biological Chemistry. 2000;275(10):7416-7423
[64] Laplante M, Sabatini DM. mTOR signaling. Cold Spring Harbor Perspectives in Biology. 
2012;4(2):a011593
[65] Pearson RB, Dennis PB, Han JW, Williamson NA, Kozma SC, Wettenhall RE, et al. The 
principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation 
site within a conserved hydrophobic domain. The EMBO Journal. 1995;14(21):5279-5287
Homeostasis - An Integrated Vision160
[66] Han J-W, Pearson RB, Dennis PB, Thomas G. Rapamycin, Wortmannin, and the methyl-
xanthine SQ20006 inactivate p70s6k by inducing dephosphorylation of the same subset 
of sites. The Journal of Biological Chemistry. 1995;270(36):21396-21403
[67] Ali SM, Sabatini DM. Structure of S6 kinase 1 determines whether raptor-mTOR or rictor-
mTOR phosphorylates its hydrophobic motif site. The Journal of Biological Chemistry. 
2005;280(20):19445-19448
[68] Düvel K, Broach JR. The role of phosphatases in TOR signaling in yeast. In: TOR. 
Springer; 2004. p. 19-38. ISBN 978-3-642-18930-2
[69] Peterson RT, Desai BN, Hardwick JS, Schreiber SL. Protein phosphatase 2A interacts 
with the 70-kDa S6 kinase and is activated by inhibition of FKBP12–rapamycin associ-
ated protein. Proceedings of the National Academy of Sciences. 1999;96(8):4438-4442
[70] Hahn K, Miranda M, Francis VA, Vendrell J, Zorzano A, Teleman AA. PP2A regulatory 
subunit PP2A-B′ counteracts S6K phosphorylation. Cell Metabolism. 2010;11(5):438-444
[71] Fenton TR, Gwalter J, Ericsson J, Gout IT. Histone acetyltransferases interact with and 
acetylate p70 ribosomal S6 kinases in vitro and in vivo. The International Journal of 
Biochemistry & Cell Biology. 2010;42(2):359-366
[72] Fenton TR, Gwalter J, Cramer R, Gout IT. S6K1 is acetylated at lysine 516 in response 
to growth factor stimulation. Biochemical and Biophysical Research Communications. 
2010;398(3):400-405
[73] Gwalter J, Wang M-L, Gout I. The ubiquitination of ribosomal S6 kinases is independent 
from the mitogen-induced phosphorylation/activation of the kinase. The International 
Journal of Biochemistry & Cell Biology. 2009;41(4):828-833
[74] Wang M-L, Panasyuk G, Gwalter J, Nemazanyy I, Fenton T, Filonenko V, et al. Regulation 
of ribosomal protein S6 kinases by ubiquitination. Biochemical and Biophysical Research 
Communications. 2008;369(2):382-387
[75] Panasyuk G, Nemazanyy I, Filonenko V, Gout I. Ribosomal protein S6 kinase 1 inter-
acts with and is ubiquitinated by ubiquitin ligase ROC1. Biochemical and Biophysical 
Research Communications. 2008;369(2):339-343
[76] Barilari M, Bonfils G, Treins C, Koka V, De Villeneuve D, Fabrega S, et al. ZRF1 is a novel 
S6 kinase substrate that drives the senescence programme. The EMBO Journal. 2017;36 
(6):736-750
[77] Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, et al. S6K1−/−/S6K2−/− mice 
exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA 
translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. 
Molecular and Cellular Biology. 2004;24(8):3112-3124
[78] Ruvinsky I, Sharon N, Lerer T, Cohen H, Stolovich-Rain M, Nir T, et al. Ribosomal pro-
tein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes & 
Development. 2005;19(18):2199-2211
[79] Holz MK, Ballif BA, Gygi SP, Blenis J. mTOR and S6K1 mediate assembly of the trans-
lation preinitiation complex through dynamic protein interchange and ordered phos-
phorylation events. Cell. 2005;123(4):569-580
S6 Kinase: A Compelling Prospect for Therapeutic Interventions
http://dx.doi.org/10.5772/intechopen.75209
161
[80] Raught B, Peiretti F, Gingras A-C, Livingstone M, Shahbazian D, Mayeur GL, et al. 
Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 
kinases. The EMBO Journal. 2004;23(8):1761-1769
[81] Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano 
M. S6K1-and \s sTRCP-mediated degradation of PDCD4 promotes protein translation 
and cell growth. Science. 2006;314(5798):467-471
[82] Wang X, Li W, Williams M, Terada N, Alessi DR, Proud CG. Regulation of elongation 
factor 2 kinase by p90RSK1 and p70 S6 kinase. The EMBO Journal. 2001;20(16):4370-4379
[83] Yamnik RL, Digilova A, Davis DC, Brodt ZN, Murphy CJ, Holz MK. S6 kinase 1 regu-
lates estrogen receptor α in control of breast cancer cell proliferation. The Journal of 
Biological Chemistry. 2009;284(10):6361-6369
[84] Hannan KM, Thomas G, Pearson RB. Activation of S6K1 (p70 ribosomal protein S6 
kinase 1) requires an initial calcium-dependent priming event involving formation of a 
high-molecular-mass signalling complex. The Biochemical Journal. 2003;370(2):469-477
[85] McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Dorfman AL, et al. Deletion 
of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like 
growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy. 
Molecular and Cellular Biology. 2004;24(14):6231-6240
[86] Nakamura JL, Garcia E, Pieper RO. S6K1 plays a key role in glial transformation. Cancer 
Research. 2008;68(16):6516-6523
[87] Hou G, Xue L, Lu Z, Fan T, Tian F, Xue Y. An activated mTOR/p70S6K signaling path-
way in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by 
rapamycin and siRNA against mTOR. Cancer Letters. 2007;253(2):236-248
[88] Wilkinson JE, Burmeister L, Brooks SV, Chan C-C, Friedline S, Harrison DE, et al. 
Rapamycin slows aging in mice. Aging Cell. 2012;11(4):675-682
[89] Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al. Inhibition of 
mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop 
in human cancer. The Journal of Clinical Investigation. 2008;118(9):3065-3074
[90] Wang X, Yue P, Chan C-B, Ye K, Ueda T, Watanabe-Fukunaga R, et al. Inhibition of 
mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and 
Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Molecular 
and Cellular Biology. 2007;27(21):7405-7413
[91] Brown MC, Gromeier M. MNK controls mTORC1: Substrate association through regula-
tion of ℡O2 binding with mTORC1. Cell Reports. 2017;18(6):1444-1457
[92] Pyronnet S, Imataka H, Gingras A-C, Fukunaga R, Hunter T, Sonenberg N. Human 
eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate 
eIF4E. The EMBO Journal. 1999;18(1):270-279
Homeostasis - An Integrated Vision162
